Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xueying, Huang, He, Xu, Bing, Guo, Hongqiang, Lin, Yingcheng, Ye, Sheng, Yi, Jiqun, Li, Wenyu, Wu, Xiangyuan, Wang, Wei, Zhan, Hongyu, Xie, Derong, Peng, Jiewen, Cao, Yabing, Pu, Xingxiang, Guo, Chengcheng, Hong, Huangming, Wang, Zhao, Fang, Xiaojie, Zhou, Yong, Lin, Suxia, Liu, Qing, Lin, Tongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639223/
https://www.ncbi.nlm.nih.gov/pubmed/30282447
http://dx.doi.org/10.4143/crt.2018.230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639223/
https://www.ncbi.nlm.nih.gov/pubmed/30282447
http://dx.doi.org/10.4143/crt.2018.230

Ejemplares similares